A New Option for Cardiorenal Protection for Patients with CKD in T2D

A New Option for Cardiorenal Protection for Patients with CKD in T2D

A New Option for Cardiorenal Protection for Patients with CKD in T2D
RestartResume

Tune in to ensure that you have the up-to-date cardiorenal data you need to improve care and outcomes for your patients with CKD in T2D.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Diabetic nephropathy is one of the leading causes of end-stage renal disease (ESRD) and is associated with mortality and morbidity worldwide. Recent data on the use of nonsteroidal MRAs were presented at the European Society of Cardiology and other major meetings and were simultaneously published in major journals. Join our experts to explore these data and find out how you can better prevent the deterioration of renal function and improve cardiovascular outcomes in your patients across the spectrum of renal decline.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
    Professor of Cardiology, National and Kapodistrian University of Athens
    Chair, Department of Cardiology, Athens University Hospital Attikon
    Chaidari, Greece

    Consulting Fees: Boehringer Ingelheim, Servier
    Commercial Interest Speakers Bureau: Boehringer Ingelheim, Novartis
    Contracted Research: Amgen, Bayer, Vifor Pharma

    Faculty:
    Javier Morales, MD, FACP, FACE
    Associate Clinical Professor of Medicine
    Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
    Hempstead, NY

    Commercial Interest Speakers Bureau: Bayer, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Inc.
    Consulting Fees: Bayer, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Inc.
    Contracted Research: Novo Nordisk, Inc.

    Angela Yee-Moon Wang, MD, PhD, FRCP
    Faculty of Medicine
    Queen Mary Hospital
    The University of Hong Kong
    Hong Kong, China

    Nothing to disclose. 

    Reviewers/Content Planners/Authors:

    • Sean Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Mario P. Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Assess the benefit-risk profiles of nonsteroidal mineralocorticoid receptor antagonists (MRAs) from recent studies of patients with chronic kidney disease (CKD) in type 2 diabetes (T2D)
    • Evaluate the potential impact of the latest clinical trial data in real-world practice for a broad spectrum of patients with CKD in T2D
    • Review new pharmacological treatment options for patients with CKD in T2D
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, PCPs, cardiologists, endocrinologists, and diabetologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Bayer AG.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free